Galactomannan in Bronchoalveolar Lavage Fluid for Diagnosis of Invasive Pulmonary Aspergillosis with Nonneutropenic Patients
Table 2
Comparison of seasonal distribution, clinical symptoms, and chest CT between proven/probable IPA patients and non-IPA patients.
Characteristics
Proven/probable IPA ()
Non-IPA ()
Age ≥ 60 years
6 (60.0)
63 (44.1 )
0.515
Male gender
8 (80.0)
77 (53.8)
0.201
Seasonal distribution, (%)
March–October
7 (70.0)
93 (65.0)
1.000
Clinical symptoms, (%)
Cough
9 (90.0)
101 (70.6)
0.340
Fever
2 (20.0)
37 (25.9)
0.971
Dyspnoea
3 (30.0)
16 (11.2)
0.212
Haemoptysis
2 (20.0)
21 (14.7)
1.000
Chest tightness
1 (10.0)
12 (8.4)
0.600
Chest pain
1 (10.0)
18 (12.6)
1.000
Chest CT, (%)
Infiltrate/Nodules
8 (80.0)
100 (69.9)
0.751
Bronchiectasis
3 (30.0)
28 (19.6)
0.700
Cavity
3 (30.0)
18 (12.6)
0.284
Air crescent sign
1 (10.0)
0
0.065
Halo sign
1 (10.0)
10 (7.0)
0.537
Other
1 (10.0)
12 (8.4)
0.600
IPA, invasive pulmonary aspergillosis; CT, computer tomography. Non-IPA patients are defined as individuals in the “non-IPA” group excluding aspergilloma, ABPA, colonization, or contamination patients.
